Malpas P J
Department of Psychological Medicine, University of Auckland, Private Bag 92019, Auckland, NZ.
J Med Ethics. 2008 Jul;34(7):548-51. doi: 10.1136/jme.2007.023101.
Within the medical, legal and bioethical literature, there has been an increasing concern that the information derived from genetic tests may be used to unfairly discriminate against individuals seeking various kinds of insurance; particularly health and life insurance. Consumer groups, the general public and those with genetic conditions have also expressed these concerns, specifically in the context of life insurance. While it is true that all insurance companies may have an interest in the information obtained from genetic tests, life insurers potentially have a very strong incentive to (want to) use genetic information to rate applicants, as individuals generally purchase their own cover and may want to take out very large policies. This paper critically focuses on genetic information in the context of life insurance. We consider whether genetic information differs in any relevant way from other kinds of non-genetic information required by and disclosed to life insurance companies by potential clients. We will argue that genetic information should not be treated any differently from other types of health information already collected from those wishing to purchase life insurance cover.
在医学、法律和生物伦理文献中,人们越来越担心基因检测得出的信息可能会被用于不公平地歧视寻求各类保险的个人,尤其是健康保险和人寿保险。消费者团体、普通公众以及患有基因疾病的人也表达了这些担忧,特别是在人寿保险方面。虽然所有保险公司可能都对从基因检测中获得的信息感兴趣,但人寿保险公司可能有非常强烈的动机(想要)利用基因信息对申请人进行评级,因为个人通常自行购买保险,并且可能想要购买保额非常高的保单。本文批判性地聚焦于人寿保险背景下的基因信息。我们思考基因信息与潜在客户向人寿保险公司提供和披露的其他非基因信息在任何相关方面是否存在差异。我们将论证,基因信息不应与已从希望购买人寿保险的人那里收集到的其他类型健康信息区别对待。